Rezolute Inc is expected to report a consensus EPS loss of $0.14 on zero revenue for the quarter ending June 30, 2026, with its current stock price of $4.22 trading significantly below the $9.38 average analyst target.
The primary focus for investors remains the status of the FDA's ongoing review of additional clinical data for lead candidate ersodetug (RZ358) in congenital hyperinsulinism.
Following a previous Phase 3 trial primary endpoint miss, the company submitted supplemental continuous glucose monitoring data in June 2026 to provide further evidence of efficacy. Shareholders are also awaiting updates on the upLIFT Phase 3 trial for tumor hyperinsulinism, which remains on track for topline results by late 2026.